&nbsp;C-Met is a tyrosine kinase receptor that is encoded in part by a mesenchymal-epidermal transition (MET) exon 14. Mutations in the MET gene can lead to increased c-MET signalling and oncogenic stimulation. Although c-MET mutation is rare, it is a targetable driver mutation.
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Incident Cases of NSCLC patients</li>
<li>Total Incident Cases of NSCLC Patients by Histology</li>
<li>Total Diagnosed Cases of NSCLC Patients by Stages</li>
<li>Total Incident Cases of C-Met NSCLC</li>
<li>Treated Patient Pool of C-Met NSCLC&nbsp;</li>
</ul>
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology&nbsp;
<ul>
<li>Total incident cases of C-Met mutated NSCLC in 7MM in 2017 were&nbsp;16,658C-Met accounted for around 4% of the total cases of NSCLC</li>
<li>The total cases of C-Met mutated NSCLC in the United States were&nbsp;7,202&nbsp;&nbsp;in 2017</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0066cc;" href="https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market" target="_blank" rel="noopener noreferrer">Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market</a>
The market size of C-Met mutated NSCLC in 7MM in 2017 was&nbsp;USD 186 million.&nbsp;&nbsp;
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Drivers
<ul>
<li>Increasing Use of Biomarker Testing&nbsp;</li>
<li>Increase in the Mutation Specific Trials Activity</li>
<li>Increasing Incidence of C-Met mutated NSCLC</li>
</ul>
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Barriers
<ul>
<li>Cost-Effectiveness of Therapies</li>
<li>Small Patient Populations of C-Met mutated NSCLC</li>
<li>Cost of Therapies</li>
<li>Burden of Disease</li>
</ul>
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Emerging Drugs
The emerging drugs of the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are&nbsp;
<ul>
<li>Tepmetko (tepotinib)</li>
<li>Merestinib</li>
<li>Telisotuzumab Vedotin</li>
<li>JNJ-61186372 (JNJ-6372)</li>
<li>Canakinumab (ACZ885)</li>
<li>Cabozantinib</li>
<li>Sym015</li>
</ul>
And many others.&nbsp;
&nbsp;
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Key Players
The key players in the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are
<ul>
<li>Novartis Pharmaceuticals</li>
<li>Merck KGaA</li>
<li>Eli Lilly and Company</li>
<li>AbbVie</li>
<li>Janssen Research &amp; Development</li>
<li>Exelixis</li>
<li>Ipsen</li>
<li>Takeda</li>
<li>Symphogen</li>
</ul>
And many others.&nbsp;

c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Market

c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.